SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disneys technical rebound and breakout attempt are drawing attention, with traders debating whether the shares can sustain upward momentum or will meet resistance again. Bulls also cite stronger parks and streaming performance in the quarterly results, while skeptics point to the stocks prolonged range-bound history and risk of another pullback.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinias third-quarter results and higher full-year revenue guidance are driving discussion, with traders noting continued LUPKYNIS growth and profitability. Despite the solid report, the share-price decline and uncertainty over the earnings call and undisclosed AUR200 indications have frustrated investors.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Attention centers on Candels planned Q4 BLA submission for CAN-2409 in localized prostate cancer and upcoming SITC pipeline data. Bulls see the clinical and regulatory milestones as potential catalysts, while skeptics point to the steep decline, CEO share sales, limited transparency, possible dilution and uncertainty about filing timing; some also blame broader biotech weakness and thin trading.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Stockholm, Sweden.

Spotify Technology S.A.

Spotifys Q3 results and upbeat Q4 outlook are driving attention: premium subscriber growth and stronger-than-expected margin and profit guidance outweighed misses on revenue and EPS. Traders are debating the sharp rally despite those misses, with bulls emphasizing subscriber momentum, improving advertising growth, and the forward outlook while skeptics point to higher expenses and weaker cash flow.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopify is drawing attention after a sharp pullback from a strong run-up ahead of earnings. Traders are split between optimism about merchant growth and AI-driven commerce, including Metas Muse integration, and concerns about valuation, fading momentum, and broader weakness in software stocks.

Astera Labs, Inc. provides rack-scale AI infrastructure through purpose-built connectivity solutions. The company offers a range of semiconductor-based connectivity solutions designed to address bandwidth, latency, and reliability challenges in AI and cloud data centers. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

ALAB is drawing attention amid a sharp pullback in AI and semiconductor stocks, with traders pointing to concern over AI spending and reports questioning OpenAIs revenue outlook as possible pressure on the sector. Bulls call the selloff an overreaction and are buying the dip, while bears argue the stocks high valuation leaves it vulnerable to further declines.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCath reimbursement could weaken in 2027 has sparked concerns about pricing and CorMedixs largest revenue driver, contributing to a sharp selloff. Traders are divided over the impact: some see a serious commercial risk, while others argue DaVitas outlook is preliminary and point to CMS reimbursement estimates as a reason the reaction may be excessive.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQs large equity and warrant offering, alongside its Elisity acquisition, has put dilution and capital allocation at the center of the discussion as shares have sold off. Bulls see the financing and acquisitions as building a broader quantum platform, while critics question shareholder costs and execution; a Google quantum breakthrough has also lifted sector optimism, though traders disagree on whether that can overcome IONQ-specific concerns.

NEAR Protocol (NEAR) is a cryptocurrency launched in 2020. NEAR Protocol has a current supply of 1,310,395,414. The last known price of NEAR Protocol is 4.30157975 USD and is up 6.10 over the last 24 hours. It is currently trading on 688 active market(s) with $1,245,620,491.67 traded over the last 24 hours. More information can be found at https://near.org/.

Near

Traders are focused on a NEAR governance vote that they say could reduce token inflation, with some viewing the votes close as a potential catalyst. Sentiment is mixed: some are accumulating in anticipation, while others expect further weakness amid Bitcoin-linked selling and liquidation concerns.

Pyth Network (PYTH) is a cryptocurrency launched in 2021and operates on the Solana platform. Pyth Network has a current supply of 9,999,981,857.422035 with 7,874,958,864.894765 in circulation. The last known price of Pyth Network is 0.06503621 USD and is up 3.48 over the last 24 hours. It is currently trading on 450 active market(s) with $50,940,939.77 traded over the last 24 hours. More information can be found at https://pyth.network/.

Pyth Network

PYTH is drawing attention for its market-data and real-world-asset narrative, especially its Nasdaq data distribution and a DAO rule directing product revenue toward PYTH accumulation; traders are also watching a teased Pyth announcement. Sentiment is mostly bullish on adoption and a price rebound, though some posts question the rallys staying power and cite token unlocks and selling pressure as risks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Bolt Biotherapeutics, Inc. (NASDAQ: BOLT)

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Bolt Biotherapeutics, Inc. (NASDAQ: BOLT)PR NewswireNEW YORK, Oct. 26, 2026 NEW YORK, Oct. 26, 2026...

The Watchlist is Heating Up Again

The names on today’s watchlist may look familiar, but the stories are moving. NeOnc Technologies Holdings (NASDAQ:NTHI) is approaching an important FDA discussion, XIAO-I Corporation (NASDAQ:AIXI) remains a high-volatility AI stock, and BIO-key International (NASDAQ:BKYI) is adding government customers in the Gulf. Meanwhile, Bolt Biotherapeutics (NASDAQ:BOLT) announced a major acquisition and financing package, Nautilus Biotechnology (NASDAQ:NAUT) is preparing to report earnings, and AI OKTO (NASDAQ:AIOK) declared a substantial special dividend. Across communications technology with ClearOne (NASDAQ:CLRO), staffing and recruiting with Robert Half (NYSE:RHI), and satellite cybersecurity with WISeSat.Space (NASDAQ: SAIQ).

Bolt Biotherapeutics Announces Acquisition Of Prana Therapies, $120 Mln Concurrent Private Placement

(RTTNews) - Friday, Bolt Biotherapeutics, Inc. (BOLT) announced its acquisition of Prana Therapies, Inc. through a stock-for-stock transaction aimed at advancing Prana's pipeline of half-life-extended multispecific antibodies developed using its proprietary INSPIRE platform...

Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Misses Revenue Estimates

Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of -53.87% and -99.67%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Oculis Holding AG (OCS) Reports Q2 Loss, Tops Revenue Estimates

Oculis Holding AG (OCS) delivered earnings and revenue surprises of +58.33% and +49.05%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Repligen (RGEN) Beats Q2 Earnings and Revenue Estimates

Repligen (RGEN) delivered earnings and revenue surprises of +20.00% and +1.09%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Lags Revenue Estimates

Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of -51.23% and -98.27%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Bolt Biotherapeutics, Inc. (BOLT) Reports Q4 Loss, Tops Revenue Estimates

Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of +10.70% and +150.00%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Beats Revenue Estimates

Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of +26.63% and +294.36%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Bolt Biotherapeutics, Inc. (BOLT) Expected to Beat Earnings Estimates: Should You Buy?

Bolt Biotherapeutics (BOLT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Its pipeline includes BDC-1001, a HER2-targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. The company was founded by Edgar G. Engleman on January 22, 2015 and is headquartered in Redwood City, CA.

Bolt Biotherapeutics Inc

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$6.59
Prev Close	$6.36
Open	$6.28
Dividend Yield	0.00%
50-Day Moving Average	$4.14
Beta	0.76
Avg. Volume	37,157.53
PE Ratio	-0.40

52-Week High	$7.78
52-Week Low	$3.10
Market Capitalization	$12.69M
EPS (Annual)	-$17.85
Price to Book	1.00
Revenue Per Employee	$334,565.22

Feed

News

Sentiment

Earnings

Fundamentals

Info

BOLT Fundamentals